Market Overview
In-vitro diagnostics (IVD) refers to tests performed on samples like blood, urine taken from the human body. IVD help detect infections like HIV, diagnose conditions like cancer, and monitor treatment of chronic diseases. It helps identify medical conditions and diseases quickly and accurately. The Mexican IVD market covers reagents, instruments, and software used to perform clinical diagnostic tests. The growing geriatric population, increasing healthcare expenditure, and rising cases of chronic diseases like cardiovascular disorders and diabetes are driving demand for IVD in Mexico. The growing awareness about early disease diagnosis is also propelling the Mexican IVD market growth.
The Global Mexico In-Vitro Diagnostics Market is estimated to be valued at US$ 1217.44 Bn in 2024 and is expected to exhibit a CAGR of 22.% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Mexico In-vitro Diagnostics market are Adtran Inc., Huawei Technologies Co. Ltd., Alcatel-Lucent S.A., Hitachi Communication Technologies, Inc., AT & T Inc., Freescale Semiconductor, Inc., Broadcom Corporation, Inc., Ericsson Inc., Calix Inc., and ECI Telecom, Ltd. These players are focusing on new product launches and expanding their manufacturing facilities in Mexico to tap the market potential.
The rising prevalence of chronic diseases is generating significant demand for IVD tests. Moreover, health campaigns for increasing awareness about early disease detection are creating lucrative opportunities. Additionally, the increasing investments by private players in the construction of diagnostics facilities and expansion of healthcare infrastructure would boost market growth over the forthcoming years.
The global expansion of key players through collaborations, partnerships, and establishing manufacturing facilities in Mexico is anticipated to provide new opportunities. Additionally, the Mexican government's focus on strengthening healthcare infrastructure and increasing healthcare expenditure would also aid market expansion during the forecast period.
Market Drivers
Growing Geriatric Population: Mexico has witnessed a rise in life expectancy and aging population over the past decade. The elderly population is more prone to chronic diseases, thus generating increased demand for IVD testing.
Increasing Healthcare Expenditure: The Mexican government has been increasing healthcare expenditure to expand and strengthen healthcare infrastructure in the country which is propelling the IVD market growth.
Market Restraints
High Capital Requirements: Setting up an IVD testing laboratory requires huge capital investments for establishing infrastructure and procuring advanced diagnostic instruments and reagents. This acts as a barrier, especially for small players.
Limited Reimbursement: Limited or no health insurance coverage and lack of proper reimbursement policies restrict the adoption of high-end IVD technologies in Mexico. This challenges market growth.
Segment Analysis
The Mexico In-Vitro Diagnostics Market is dominated by the molecular diagnostics segment. Molecular diagnostics tests provide direct and accurate detection of genetic material of causative microorganisms including bacteria and viruses. Such tests reduce diagnosis time and help in quick administration of appropriate treatment. Growing burden of infectious diseases, rise in usage of polymerase chain reaction (PCR) technique and availability of automated molecular diagnostics instruments are driving growth of this segment in Mexico. The clinical chemistry segment is the second largest sub-segment owing to increasing prevalence of lifestyle diseases like diabetes and cardiovascular conditions requiring regular biochemical monitoring.
Global Analysis
The North America region currently dominates the Mexico in-vitro diagnostics market. Factors such as robust healthcare infrastructure, major presence of leading manufacturers, and demand for advanced diagnostic technologies drive market growth in this region. The US accounts for the largest share in North America owing to high adoption of personalized medicine, companion diagnostics, and point-of-care testing. The Mexico market in Latin America is expected to grow at the fastest pace during the forecast period. This is due to increasing healthcare investments by both public and private players, rising disease burden, and growing awareness regarding early disease diagnosis in the country.
Comments
0 comment